Latest posts from
What is New in Respiratory Medicine
Facebook Group
-
Saturday 10 Oct 2020
Although antibodies to SARS-CoV-2 might wane over time, researchers suggest memory B cell immunity could remain and ramp up quickly to prevent severe re-infections.
-
Saturday 10 Oct 2020
Thoracic ultrasound is increasingly considered to be an essential tool for the pulmonologist. It is used in diverse clinical scenarios, including as an adjunct to clinical decision making for diagnosis, a real-time guide to procedures, and a predictor or measurement of treatment response. The aim of...
-
Saturday 10 Oct 2020
Prone Positioning for Acute Respiratory Distress Syndrome (ARDS) - information for patients (also with COVID-19)
jamanetwork.com
Patient Information: Prone Positioning for Acute Respiratory Distress Syndrome (ARDS)
This JAMA Patient Page describes the technique of prone positioning during acute respiratory distress syndrome (ARDS), the possible benefits of prone positioning for patients hospitalized with COVID-19, and the risks involved.
-
Friday 09 Oct 2020
Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19.
Among patients hospitalized with Covid-19, those who received hydroxychloroquine did not have a lower incidence of death at 28 days than those who received usual care.
Original Article from The New England Journal of Medicine — Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19
-
Thursday 08 Oct 2020
Severe asthma UBIOPRED paper looking at how allergic sensitisation is associated with severe asthma across the whole life course is now published in JACI:
Allergic sensitization is associated with severe asthma, but assessment of sensitization is not recommended by most guidelines.
-
Thursday 08 Oct 2020
Rescue Therapy for Pregnant Women with Severe COVID-19. https://jwat.ch/2F7c2WS #COVID19 #pregnancy
-
Thursday 08 Oct 2020
Wearing face mask unlikely to cause overexposure to CO2, even in those with lung disease
In a new study, wearing a surgical face mask did not cause gas exchange abnormalities in healthy adults or in adults with lung function impairment, researchers reported in the Annals of the American Thoracic Society. “It is important to inform the public that the discomfort associated with mas...
-
Thursday 08 Oct 2020
Convalescent blood plasma is currently the only therapy against COVID-19 associated with a major reduction in mortality if given before ICU admission.
-
Thursday 08 Oct 2020
ERS / ATS Task Force Guidance on COVID-19 management
Background Coronavirus disease 2019 (COVID-19) is a disease caused by severe acute respiratory syndrome-coronavirus-2. Consensus suggestions can standardise care, thereby improving outcomes and facilitating future research. Methods An International Task Force was composed and agreement regarding cou...
-
Thursday 08 Oct 2020
In acutely ill patients, the usual 30 s to count breathing are insufficient to give a reliable measurement
Background Respiratory rate is a basic clinical measurement used for illness assessment. Errors in measuring respiratory rate are attributed to observer and equipment problems. Previous studies commonly report rate differences ranging from 2 to 6 breaths·min−1 between observers. Methods To stud...
-
Thursday 08 Oct 2020
Machine Learning Classifier Models: The Future for Acute Respiratory Distress Syndrome Phenotyping?
Acute respiratory distress syndrome (ARDS) is a heterogeneous clinical syndrome characterized by severe respiratory failure requiring mechanical ventilatory support for which there is no therapy and in which mortality remains approximately 40% (1, 2). A recent important advance has been the subclass...
-
Thursday 08 Oct 2020
Dupilumab is effective in type 2-high asthma patients receiving high-dose inhaled corticosteroids at baseline.
Dupilumab is effective in type 2-high asthma patients receiving high-dose inhaled corticosteroids at baseline. Oct 5, 2020 Dupilumab blocks the shared receptor component for interleukin (IL)-4/IL-13, key drivers of type 2 inflammation. In phase 2b (NCT01854047) and phase 3 LIBERTY ASTHMA QUEST (NCT0...
-
Thursday 08 Oct 2020
Systemic Complement Activation Associated With Respiratory Failure in COVID-19
Researchers sought to identify the degree and time point of systemic complement activation in coronavirus disease 2019.
-
Thursday 08 Oct 2020
N I N E hours! (compared to 1.8h of the IAV).
"The 9-h survival of SARS-CoV-2 on human skin may increase the risk of contact transmission in comparison with IAV, thus accelerating the pandemic. Proper hand hygiene is important to prevent the spread of SARS-CoV-2 infections."
AbstractBackground. The stability of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on human skin remains unknown, considering the hazards of
-
Thursday 08 Oct 2020
Adherence to a high-fiber diet may aid in mediating systemic inflammation and decrease the risk for respiratory morbidity, including #asthma.
Adherence to a high-fiber diet may aid in mediating systemic inflammation and decrease the risk for respiratory morbidity, including asthma, according to study results published in the Annals of the American Thoracic Society. Muhammad A. Saeed, MD,research associate in the division of pulmonary, cri...
-
Thursday 08 Oct 2020
This open label clinical trial compares the effects of dexamethasone vs usual care on the number of days alive and free of mechanical ventilation at day 28 among COVID-19 patients in Brazil with moderate to severe acute respiratory distress syndrome (ARDS).
-
Wednesday 07 Oct 2020
When data from five randomized controlled trials of hydroxychloroquine for COVID-19 prevention or treatment were pooled for a meta-analysis, researchers found that early use of the drug by people who were not hospitalized yielded a statistically significant 24% reduction in risk of infection, hospit...
-
Wednesday 07 Oct 2020
Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
In patients admitted to hospital with COVID-19, lopinavir–ritonavir was not associated with reductions in 28-day mortality, duration of hospital stay, or risk of progressing to invasive mechanical ventilation or death. These findings do not support the use of lopinavir–ritonavir for treatment of patients admitted to hospital with COVID-19.
In patients admitted to hospital with COVID-19, lopinavir–ritonavir was not associated with reductions in 28-day mortality, duration of hospital stay, or risk of progressing to invasive mechanical ventilation or death. These findings do not support the use of lopinavir–ritonavir for treatment of...
-
Tuesday 06 Oct 2020
Environmental exposures could alter the expression of asthma susceptibility genes and lead to asthma pathogenesis. A letter to the editor reports a transcriptome-wide study of nasal epithelium and atopic asthma in Puerto Rican children.
Asthma affects approximately 7 million children in the United States, where approximately 11% to 13% of children report respiratory or skin allergies. Genetic variants identified in large genome-wide association studies explain only a modest proportion of asthma risk, suggesting a substantial contri...
-
Tuesday 06 Oct 2020
Always consider an underlying diagnosis of Aspergillus-related disease when faced with persistent symptoms in an individual with predisposing risk factors (e.g. asthma)
A 66-year-old, female, lifelong nonsmoker was referred to the chest clinic on an urgent referral pathway. She presented with dry cough and breathlessness of 6 months duration on a background of intermittent cough for 5 years. She had no sputum production, haemoptysis or weight loss, and maintain...
